Impact of Inititing Biologics in Patients With Severe Asthma on Long-term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Chen, Wenjia; Tran, Trung N.; Sadatsafavi, Mohsen; Murray, Ruth; Wong, Nigel Chong Boon; Ali, Nasloon; Ariti, Con; Bulathsinhala, Lakmini; Gil, Esther Garcia; FitzGerald, J. Mark; Alacqua, Marianna; Al-Ahmad, Mona; Altraja, Alan; Al-Lehebi, Riyad; Bhutani, Mohit; Bjermer, Leif Hilding; Bjerrum, Anne-Sofie; Bourdin, Arnaud; von Bülow, Anna; Busby, John; Canonica, Giorgio Walter; Carter, Victoria; Christoff, George C.; Cosio, Borja G.; Costello, Richard W.; Fonseca, João A.; Gibson, Peter G.; Yoo, Kwang-Ha; Heaney, Liam G.; Heffler, Enrico; Hew, Mark; Hilberg, Ole; Hoyte, Flavia; Iwanaga, Takashi; Jackson, David J.; Jones, Rupert C.; Koh, Mariko Siyue; Kuna, Piotr; Larenas-Linnemann, Désirée; Lehmann, Sverre; Lehtimäki, Lauri; Lyu, Juntao; Mahboub, Bassam; Maspero, Jorge; Menzies-Gow, Andrew N.; Newell, Anthony; Sirena, Concetta; Papadopoulos, Nikolaos G.; Papaioannou, Andriana I.; Perez-de-Llano, Luis; Perng (Steve), Diahn-Warng; Peters, Matthew; Pfeffer, Paul E.; Porsbjerg, Celeste M.; Popov, Todor A.; Rhee, Chin Kook; Salvi, Sundeep; Taillé, Camille; Taube, Christian; Torres-Duque, Carlos A.; Ulrik, Charlotte; Ra, Seung-Won; Wang, Eileen; Wechsler, Michael E.; Price, David B.
Journal article, Peer reviewed
Published version
![Thumbnail](/bora-xmlui/bitstream/handle/11250/3112697/1-s2.0-S2213219823006438-main.pdf.jpg?sequence=6&isAllowed=y)
View/ Open
Date
2023Metadata
Show full item recordCollections
- Department of Clinical Science [2379]
- Registrations from Cristin [10237]
Original version
Journal of Allergy and Clinical Immunology: In Practice. 2023, 11 (9), 2732-2747. 10.1016/j.jaip.2023.05.044Abstract
Background
Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone.
Objective
To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS.
Methods
This was a propensity score–matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models.
Results
We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]).
Conclusions
In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization.